National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States (1985)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix L: Prospects for Immunizing Against Neisseria gonorrhoeae." New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States. Washington, DC: The National Academies Press, 1985.

Please select a format:

BibTeX EndNote RefMan


Page
384
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States

Institutes of Health, Pub. No. 81–2213. Washington, D.C.: U.S. Government Printing Office.

Noegel, A., and E.C.Gotschlich. 1983. Isolation of a high molecular weight polyphosphate from Neisseria gonorrhoeae. J. Exp. Med. 157(6):2049–2060.

Norqvist, A., J.Davies, L.Norlander, and S.Normark. 1978. The effect of iron starvation on the outer membrane protein composition of Neisseria gonorrhoeae. FEMS Microbiol. Lett. 4:71–75.

O’Hare, P.A., N.J.Fiumara, and W.M.McCormack. 1980. Pelvic inflammatory disease among women presenting to emergency rooms of hospitals in Massachusetts. Am. J. Obstet. Gynecol. 138(7):909–912.

Platt, R., P.A.Rice, and W.M.McCormack. 1983. Risk of acquiring gonorrhea and prevalance of abnormal adnexal findings among women recently exposed to gonorrhea. JAMA 250(23):3205–3209.

Plaut, A.G., J.V.Gilbert, M.S.Artenstein, and J.D.Capra. 1975. Neisseria gonorrhoeae and Neisseria meningitidis: extracellular enzyme cleaves human immunoglobulin A. Science 190:1103–1105.

Rendtorff, R.C., J.W.Curran, R.W.Chandler, W.L.Wiser, and H.Robinson. 1974. Economic consequences of gonorrhea in women: experience from an urban hospital. J. Am. Vener. Dis. Assoc. 1(1):40–47.

Richardson, W.P., and J.C.Sadoff. 1977. Production of a capsule by Neisseria gonorrhoeae. Infect. Immun. 15(2):663–664.

Sadoff, J.C. 1984. Personal communication, Uniformed Services University of the Health Sciences, Bethesda, Md.

Schoolnik G.K., J.Y.Tai, and E.C.Gotschlich. 1983. A pilus peptide vaccine for the prevention of gonorrhea. Progr. Allergy 33:314–331.

Siegel, M., D.Olsen, C.Critchlow, and T.M.Buchanan. 1982. Gonococcal pili: safety and immunogenicity in humans and antibody function in vitro. J. Infect. Dis. 145(3):300–310.

Tramont, E.C. 1977. Inhibition of adherence of Neisseria gonorrhoeae by human genital secretions. J. Clin. Invest. 59:117–124.

Tramont, E.C., and C.C.Brinton. 1984. Clinical evaluation and laboratory evaluation of gonococcal pili. Presented at a conference on Ontogeny of Immune Function and Pathogenic Mechanisms Involved in Bacterial Vaccine Development, Sept. 17–20, 1984, National Institutes of Health, Bethesda, Md.

Tramont, E.C., J.Ciak, J.Boslego, D.G.McChesney, C.C.Brinton, and W.Zollinger. 1980. Antigenic specificity of antibodies in vaginal secretions during infection with Neisseria gonorrhoeae. J. Infect. Dis. 142(1):23–31.

Tramont, E.C., J.C.Sadoff, J.W.Boslego, J.Ciak, D.McChesney, C.C. Brinton, S.Wood, and E.Takafuji. 1981. Gonococcal pilus vaccine: studies of antigenicity and inhibition of attachment. J. Clin. Invest. 68(4):881–888.

Washington, A.E., W.Cates, Jr., and A.A.Zaidi. 1984. Hospitalizations for pelvic inflammatory disease. Epidemiology and trends in the United States, 1975–1981. JAMA 251(19):2529–2533.

Wiesner, P.J., and S.E.Thompson, III. 1982. Gonococcal infections. Pp. 235–257 in Bacterial Infections of Humans, A.S.Evans and H.A. Feldman, eds. New York: Plenum.

Page
384
Front Matter (R1-R14)
1. Summary (1-16)
2. Priority Setting for Health Related Investments: A Review of Methods (17-27)
3. Overview of the Analytic Approach (28-38)
4. Comparison of Disease Burdens and Costs (39-58)
5. Predictions on Vaccine Development (59-66)
6. Assessing the Likely Utilization of New Vaccines (67-91)
7. Calculation and Comparison of the Health Benefits and Costs Associated with Candidate Vaccines (92-120)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (121-126)
9. Findings, Conclusions, and Recommendations (127-148)
Appendix A: Some Examples of the Application of Project Selection Method (149-152)
Appendix B: Pathogenic Agents for Which Accelerated Vaccine Development Does Not Appear Appropriate (153-170)
Appendix C: Prospects for Immunizing Against Bordetella pertussis (171-182)
Appendix D: Prospects for Immunizing Against Coccidioidomycosis (183-197)
Appendix E: Prospects for Immunizing Against Cytomegalovirus (198-234)
Appendix F: Prospects for Immunizing Against Hemophilus influenzae type b (235-251)
Appendix G: Prospects for Immunizing Against Hepatitis A Virus (252-260)
Appendix H: Prospects for Immunizing Against Hepatitis B Virus (261-279)
Appendix I: Prospects for Immunizing Against Herpes Simplex Viruses 1 and 2 (280-312)
Appendix J: Prospects for Immunizing Against Herpesvirus varicellae (313-341)
Appendix K: Prospects for Immunizing Against Influenza Viruses A and B (342-364)
Appendix L: Prospects for Immunizing Against Neisseria gonorrhoeae (365-384)
Appendix M: Prospects for Immunizing Against Parainfluenza Viruses (385-396)
Appendix N: Prospects for Immunizing Against Respiratory Syncytial Virus (397-409)
Appendix O: Prospects for Immunizing Against Rotavirus (410-423)
Appendix P: Prospects for Immunizing Against Streptococcus group B (424-439)
Appendix Q: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (440-443)
Appendix R: Technical Notes (444-444)
Appendix S: Biographical Notes on Committee Members (445-449)
Appendix T: Additional Sources of Advice to the Committee (450-452)
Index (453-458)